Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL. Cherny NI, et al. Among authors: zygoura p. J Clin Oncol. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17. J Clin Oncol. 2019. PMID: 30707056
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.
Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A. Rulle U, et al. Among authors: zygoura p. J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18. J Thorac Oncol. 2018. PMID: 30240851 Free article.
Report on the status of women occupying leadership roles in oncology.
Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Hofstädter-Thalmann E, et al. Among authors: zygoura p. ESMO Open. 2018 Sep 21;3(6):e000423. doi: 10.1136/esmoopen-2018-000423. eCollection 2018. ESMO Open. 2018. PMID: 30273418 Free PMC article.
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey.
Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G MD, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Banerjee S, et al. Among authors: zygoura p. ESMO Open. 2018 Sep 21;3(6):e000422. doi: 10.1136/esmoopen-2018-000422. eCollection 2018. ESMO Open. 2018. PMID: 30273420 Free PMC article.
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.
Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, Jäger U, Latino NJ, Douillard JY, Malcovati L, Mateos MV, Ossenkoppele GJ, Porkka K, Raderer M MD, Ribera JM, Scarfò L, Wester R, Zygoura P, Sonneveld P. Kiesewetter B, et al. Among authors: zygoura p. ESMO Open. 2020 Jan;5(1):e000611. doi: 10.1136/esmoopen-2019-000611. ESMO Open. 2020. PMID: 31958292 Free PMC article.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Gyawali B, et al. Among authors: zygoura p. ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20. ESMO Open. 2021. PMID: 33887690 Free PMC article. Review.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruysscher D; ETOP/IFCT 4-12 STIMULI Collaborators. Peters S, et al. Ann Oncol. 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. Epub 2021 Sep 23. Ann Oncol. 2022. PMID: 34562610 Free article. Clinical Trial.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
27 results